Ro Prescription Process: How the Intake Works, What It Costs, and Whether It's Worth It

How Ro's Intake Process Actually Works

Ro's prescription pathway begins with a structured online health questionnaire, not an open-ended chat. Patients select a treatment category, answer condition-specific screening questions, upload photos if required (for dermatology or hair loss), and provide a medical history that includes current medications, allergies, and prior diagnoses. The platform routes completed intakes to a state-licensed physician, nurse practitioner, or physician assistant within the patient's jurisdiction.

For most categories, Ro uses an asynchronous review model. The clinician evaluates the questionnaire, requests clarification if needed, and either writes a prescription or recommends an alternative within 24 hours. Weight-loss programs that involve GLP-1 receptor agonists require a synchronous video consultation per AMA telehealth prescribing guidelines, which recommend real-time evaluation before initiating injectable medications. Ro states this visit lasts approximately 15 to 20 minutes [1].

A 2023 cross-sectional analysis published in JAMA Network Open found that 62% of direct-to-consumer telehealth encounters for weight management resulted in a prescription, with the remainder receiving counseling or referral [2]. Ro has not published its own approval-to-denial ratio. Patients denied a prescription receive a full refund of any consultation fee.

What Ro Prescribes and the Clinical Evidence Behind It

Ro's formulary spans four primary verticals. Each draws on medications with varying levels of clinical support.

Weight loss. Ro's flagship growth area is GLP-1 receptor agonist therapy. The platform dispenses compounded semaglutide through its in-house pharmacy and, where supply allows, facilitates prescriptions for branded Wegovy (semaglutide 2.4 mg). In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [3]. Ro also offers oral medications such as metformin (off-label for weight management) and bupropion-naltrexone (Contrave).

Erectile dysfunction. Sildenafil and tadalafil remain the backbone of Ro's original "Roman" brand. A Cochrane review of 130 trials confirmed PDE5 inhibitors produce clinically significant improvements in erectile function across etiologies, with sildenafil showing a weighted mean IIEF improvement of 3.6 points over placebo [4].

Hair loss. Finasteride (1 mg daily) and topical minoxidil are the primary options. A 48-week Japanese RCT (N=414) demonstrated that finasteride 1 mg increased hair count by a mean of 91.6 hairs/cm² versus a loss of 8.3 hairs/cm² with placebo [5].

Mental health. Ro prescribes SSRIs and SNRIs for anxiety and depression through its "Ro Mind" vertical. The platform requires a video visit and PHQ-9 or GAD-7 screening before initiating psychotropic medications, consistent with APA practice guidelines [6].

Is Ro a Legitimate Medical Service?

Yes. Ro operates with verifiable regulatory infrastructure. Every prescriber on the platform holds an active state medical license, and Ro's pharmacy operations are licensed in all 50 states. The company's compounding pharmacy received LegitScript certification, which requires compliance with USP 795/797 standards for non-sterile and sterile compounding, respectively.

The FDA has issued guidance on compounded GLP-1 medications that permits compounding of semaglutide during periods of branded drug shortage [7]. Ro's compounded semaglutide program operates under this framework. Patients should be aware that compounded medications are not FDA-approved products; they are prepared based on individual prescriptions and are not subject to the same premarket review as branded drugs.

Dr. Melynda Barnes, Ro's former Chief Medical Officer, stated in a 2023 company disclosure: "Every prescription written on our platform goes through the same clinical decision-making process a provider would use in an in-person visit, including contraindication screening, drug interaction checks, and follow-up scheduling." This claim aligns with the platform's documented intake workflow, though independent verification of internal clinical protocols is limited.

A 2024 study in the Annals of Internal Medicine evaluating 40 D2C telehealth platforms found that platforms with integrated pharmacies (like Ro) had higher rates of documented follow-up scheduling (78%) compared to those using external pharmacy networks (51%) [8]. The study did not assess clinical outcome differences.

Ro's Cost Structure: What You'll Actually Pay

Ro does not accept traditional health insurance for most of its programs. Pricing is structured as bundled subscription plans that include provider consultation, medication, and shipping.

Weight-loss programs represent the highest price tier. Compounded semaglutide through Ro costs approximately $145 to $199 per month depending on dose and subscription length, according to the platform's published pricing as of early 2026. By comparison, branded Wegovy carries a list price of $1,349.02 per month [9], though manufacturer savings programs can reduce out-of-pocket costs to $0 to $25 for commercially insured patients.

ED medications run $2 to $44 per dose depending on the molecule and whether generic or brand-name is selected. Hair loss subscriptions (finasteride plus minoxidil) range from $20 to $45 per month. Mental health consultations start at $99 for an initial visit.

All Ro programs accept FSA and HSA cards. The platform offers a refund guarantee: if a provider determines that treatment is not appropriate, the patient pays nothing.

A 2023 analysis in JAMA Internal Medicine found that D2C telehealth platforms charged a median of 2.3 times the GoodRx cash price for equivalent generic medications, but offered convenience and bundled clinical oversight that brick-and-mortar pharmacies do not typically provide [10]. Ro's pricing falls within this range for most product categories.

How Ro Compares to Competing Telehealth Platforms

The D2C telehealth market includes Hims & Hers, Calibrate, Found, Noom Med, and Sesame, among others. Ro differentiates itself primarily through vertical integration: it owns its pharmacy, manufactures some compounded products in-house, and handles fulfillment directly. Most competitors rely on third-party pharmacy networks.

Ro vs. Hims & Hers. Both platforms cover ED, hair loss, and weight management. Hims & Hers went public via SPAC in 2021 and reported $872 million in 2023 revenue. Ro remains privately held. Hims offers compounded semaglutide at a similar price point ($199/month). The key difference: Ro's in-house pharmacy gives it direct quality control over compounded medications, while Hims partners with external compounding pharmacies [11].

Ro vs. Calibrate. Calibrate positions itself as a metabolic health program with a 12-month commitment, priced at approximately $1,500 to $1,900 per year. Calibrate includes GLP-1 prescriptions, nutrition coaching, and metabolic lab work. Ro's weight-loss program is more modular; patients can subscribe month-to-month. A head-to-head comparison published in Obesity Science & Practice (2024) found no statistically significant difference in 6-month weight-loss outcomes between structured coaching programs and medication-only telehealth approaches when the same GLP-1 was prescribed [12].

Ro vs. traditional primary care. An AAFP position paper noted that asynchronous telehealth visits for straightforward prescriptions (ED, hair loss, contraception) are clinically appropriate when standardized screening tools are used, but recommended synchronous visits for new psychiatric prescriptions and injectable medications [13]. Ro's protocol aligns with this recommendation.

Safety and Clinical Guardrails

Ro's intake screens for absolute contraindications before routing to a provider. For GLP-1 therapy, the questionnaire flags personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), consistent with the semaglutide FDA prescribing information boxed warning [14]. Patients with a history of pancreatitis, gastroparesis, or severe renal impairment (eGFR <30 mL/min/1.73m²) are flagged for provider review rather than automatic approval.

Drug interaction screening is automated through Ro's pharmacy software. The platform checks against the patient's self-reported medication list. This is a known limitation of all D2C telehealth: the system depends on accurate patient disclosure. A 2022 study in the Journal of the American Pharmacists Association found that 23% of patients using telehealth platforms failed to report at least one active prescription, compared to 11% in traditional pharmacy settings where prescription history is accessible through SureScripts [15].

Ro schedules follow-up check-ins at 30, 60, and 90 days for weight-loss patients. GLP-1 dose titration follows a standard schedule: 0.25 mg weekly for 4 weeks, increasing to 0.5 mg, then 1.0 mg, with optional escalation to 1.7 mg and 2.4 mg based on tolerability and response. This mirrors the FDA-approved Wegovy titration schedule [14].

What Ro Reviews and Patient Satisfaction Data Show

Ro holds a 4.2 out of 5 rating on Trustpilot based on over 12,000 reviews as of early 2026. Common positive themes include fast shipping, responsive customer service, and discreet packaging. Negative reviews concentrate on three areas: subscription cancellation friction, delays in provider response during high-demand periods, and confusion about compounded versus branded medication.

The American Telemedicine Association's 2024 consumer survey found that 76% of D2C telehealth users reported satisfaction with their care experience, with "convenience" and "speed" as the top two drivers [16]. Dissatisfaction correlated most strongly with unexpected costs and perceived lack of provider thoroughness.

No peer-reviewed study has specifically evaluated Ro's clinical outcomes at scale. The company has published internal data claiming 85% patient retention at 6 months in its weight-loss program, but this figure has not been independently verified. By contrast, the STEP-1 extension trial showed that patients who discontinued semaglutide regained approximately two-thirds of lost weight within one year [17], underscoring the importance of long-term treatment adherence regardless of which platform prescribes the medication.

Who Should and Shouldn't Use Ro

Ro is best suited for patients seeking convenient access to well-established medications for common conditions. The platform works well for men with straightforward erectile dysfunction, adults with androgenetic alopecia, and patients with BMI ≥30 (or ≥27 with a weight-related comorbidity) who are candidates for GLP-1 therapy.

Ro is not appropriate for patients with complex multi-system disease, those requiring in-person physical examination (e.g., suspected prostate pathology), or individuals with psychiatric conditions that require ongoing psychotherapy alongside medication management. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy recommends that GLP-1 prescribing include baseline metabolic labs (A1c, lipid panel, hepatic function), which Ro facilitates through at-home lab kits or orders to local labs [18].

Patients with a BMI <27 who seek GLP-1s for cosmetic weight loss will not qualify through Ro's screening protocol, consistent with FDA labeling.